Literature DB >> 3492553

Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption.

P Stashenko, F E Dewhirst, W J Peros, R L Kent, J M Ago.   

Abstract

Cytokines with bone-resorbing activity include IL 1 beta (pI 7), IL 1 alpha (pI 5), tumor necrosis factor (TNF), and lymphotoxin (LT). Possible interaction between IL 1 beta, the major mediator with osteoclast-activating factor (OAF) activity, and other cytokines was studied. By itself, IL 1 beta was 13-fold more potent than IL 1 alpha and 1000-fold more potent than either TNF or LT in stimulating bone resorption. Suboptimal concentrations of IL 1 beta or IL 1 alpha in combination with suboptimal concentrations of TNF or LT resulted in synergistic bone-resorptive responses (1.5 to 10 times the expected responses if their effects were additive). Synergy between either form of IL 1 and TNF or LT resulted in a twofold increase in activity of IL 1, and a 100-fold increase in activity of TNF or LT. However, even with optimal synergy, IL 1 beta remained 20-fold more potent in inducing bone resorption than TNF or LT. Because IL 1 beta is considerably more potent than TNF and LT in stimulating bone resorption either alone or under synergistic conditions, it is unlikely that TNF and LT are responsible for more than a minor proportion of the total bone-resorbing activity formerly referred to as OAF.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492553

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  80 in total

Review 1.  Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?

Authors:  J Ciampolini; K G Harding
Journal:  Postgrad Med J       Date:  2000-08       Impact factor: 2.401

2.  Bacterium-dependent induction of cytokines in mononuclear cells and their pathologic consequences in vivo.

Authors:  Y Jiang; L Magli; M Russo
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Monocyte recruitment and expression of monocyte chemoattractant protein-1 are developmentally regulated in remodeling bone in the mouse.

Authors:  S Volejnikova; M Laskari; S C Marks; D T Graves
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

4.  Actinobacillus actinomycetemcomitans serotype b-specific polysaccharide antigen stimulates production of chemotactic factors and inflammatory cytokines by human monocytes.

Authors:  N Yamaguchi; Y Yamashita; D Ikeda; T Koga
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 5.  Bacterially induced bone destruction: mechanisms and misconceptions.

Authors:  S P Nair; S Meghji; M Wilson; K Reddi; P White; B Henderson
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

6.  Interleukin-1 and tumor necrosis factor receptor signaling is not required for bacteria-induced osteoclastogenesis and bone loss but is essential for protecting the host from a mixed anaerobic infection.

Authors:  C P Chen; M Hertzberg; Y Jiang; D T Graves
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

7.  Detection of inflammatory cytokine messenger RNA (mRNA)-expressing cells in human inflamed gingiva by combined in situ hybridization and immunohistochemistry.

Authors:  Y Matsuki; T Yamamoto; K Hara
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

Review 8.  Novel host response therapeutic approaches to treat periodontal diseases.

Authors:  Keith L Kirkwood; Joni A Cirelli; Jill E Rogers; William V Giannobile
Journal:  Periodontol 2000       Date:  2007       Impact factor: 7.589

9.  Periprosthetic osteolysis: characterizing the innate immune response to titanium wear-particles.

Authors:  Christine A St Pierre; Melvin Chan; Yoichiro Iwakura; David C Ayers; Evelyn A Kurt-Jones; Robert W Finberg
Journal:  J Orthop Res       Date:  2010-11       Impact factor: 3.494

10.  Tumour necrosis factor in synovial exudates.

Authors:  F S Di Giovine; G Nuki; G W Duff
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.